For Returning Patients
For New Patients
Menu
For Returning Patients
For New Patients
Here’s a taste of the medical literature that discusses LDN
Arthritis Rheum. 2013 Feb;65(2):529-38. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Younger J1, Noor N, McCue R, Mackey S.
Front Immunol. 2017; 8: 809. Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors Rachel Cant,1,* Angus G. Dalgleish,1 and Rachel L. Allen1
Clin Rheumatol. 2014 Apr;33(4):451-9. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Younger J1, Parkitny L, McLain D.
J Neuroimmune Pharmacol. 2013 Jun; 8(3): 470–476. Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN) Pradeep Chopra
and Mark S. Cooper
Mult Scler J Exp Transl Clin. 2016 Jan-Dec; 2: 2055217316672242. Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis
J Clin Gastroenterol. 2012 Nov 21. [Epub ahead of print]
Safety and Tolerability of Low-dose Naltrexone Therapy in Children With Moderate to Severe Crohn’s Disease: A Pilot Study. Smith JP, Field D, Bingaman SI, Evans R, Mauger DT.
Dig Dis Sci. 2006 Dec;51(12):2128-33. Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study. Kariv R1, Tiomny E, Grenshpon R, Dekel R, Waisman G, Ringel Y, Halpern Z.
Dig Dis Sci. 2011 July ; 56(7): 2088–2097. Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn’s Disease: A Randomized Placebo-Controlled Trial
Join my free email newsletter and get high-quality information about healing chronic illness and pain